Activity at factories in the central U.S. eked out growth in December, cooling from last month's activity as production and labor-market measures dragged. ...

Key Takeaways CLSK's valuation looks stretched as its forward P/E of 50.83X far exceeds the industry average.CleanSpark's revenues and earnings remain tightly linked to Bitcoin prices, amplifying volatility risk.AI and HPC expansion is still unproven for CLSK amid rising competition and declining earnings estimates.CleanSpark, Inc. (CLSK) is a leading U.S. Bitcoin miner and data-center operator that is expanding beyond crypto mining into high-performance computing (HPC) and artificial intelligence (AI) infr ...

Key Takeaways CME gains from market volatility, with clearing and transaction fees remaining its largest revenue driver. CME is seeing higher crypto trading activity, aided by growing participation in the crypto economy. CME's strong cash flow supports dividends, and investments in data, products, and clearing services. Shares of CME Group Inc. (CME) have gained 15.5% in the past year, outperforming the industry's growth of 8.1%. CME Group has outperformed its peers, including Intercontinental Exchange Inc. ...

March corn (ZCH26) futures present a buying opportunity on more price strength. See on the daily bar chart for March corn futures that prices have this week rebounded from a strong support area and that a bullish double-bottom reversal pattern may now be forming. More News from Barchart Fundamentally, export and domestic demand for U.S. corn has been solid the past few months. A move in March corn futures above chart resistance at $4.45 would give the bulls more power and it would also become a buying ...

Industry Overview - The global oncology market is evolving significantly due to rising cancer incidence and rapid scientific advancements, with the American Cancer Society estimating approximately 2.04 million new cancer diagnoses and over 618,000 cancer-related deaths in the U.S. by 2025 [2] - Aging populations and lifestyle-related risk factors are contributing to higher cancer prevalence, leading to sustained growth in healthcare spending on oncology [2] Innovation in Cancer Care - Breakthroughs in immunotherapies, targeted treatments, and personalized vaccines are expanding therapeutic options beyond conventional chemotherapy and radiation [3] - Immune-based strategies, including checkpoint inhibitors and CAR-T therapies, are harnessing the body's immune system to target tumors, while targeted therapies focus on specific genetic alterations [3] - Emerging technologies like genomic sequencing, AI, and machine learning are enhancing biomarker discovery and supporting earlier diagnosis, improving survival rates and quality of life across several cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, Johnson & Johnson (J&J), Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly, are investing aggressively in oncology portfolios with new therapies such as antibody-drug conjugates and bispecific antibodies [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing agreements, and acquisitions [5] Market Dynamics - Oncology is considered one of the most durable and attractive segments within the global healthcare sector for long-term investors, supported by ongoing innovation and favorable reimbursement dynamics [6] Company Focus: Johnson & Johnson - J&J's oncology segment currently accounts for approximately 27% of its total revenues, with oncology sales rising 20.6% to $18.52 billion in the first nine months, driven by key products like Darzalex and Erleada [9] - J&J's oncology pipeline has gained momentum with promising developments in colorectal and head and neck cancers, and the company expects its oncology sales to reach $50 billion by the end of the decade [10][12] - J&J is also enhancing its oncology pipeline through M&A, including a recent agreement to acquire Halda Therapeutics [11] Company Focus: ImmunityBio - ImmunityBio's lead drug, Anktiva, was approved for treating BCG-unresponsive non-muscle invasive bladder cancer, generating $74.7 million in sales with a 467% increase in volume [13] - The drug is under review in the EU, and ImmunityBio is evaluating Anktiva for expanded use in other cancer indications [15] Company Focus: Foghorn Therapeutics - Foghorn Therapeutics is developing precision therapies targeting genetically driven vulnerabilities, with a collaboration with Lilly to co-develop its selective SMARCA2 oncology program [17] - Foghorn's lead candidate, FHD-909, is advancing in a phase I study for SMARCA4-mutated cancers, with initial data expected in 2026 [17][18]

Even one small tweak before year-end can prevent an unpleasant surprise next spring—and keep your cash flow steady heading into 2026.Hit a safe harbor. Rogé recommended paying "90% of this year's tax or 100% of last year's (110% if adjusted gross income (AGI) exceeded $150,000). If you're off track in November, adjust W-4s now so payroll can fix the glide path instead of your April checkbook."Watch special situations. Side gig holders who don't make estimated payments and new retirees who began required min ...

PRESS RELEASE REGULATED INFORMATIONBrussels, 18 December 2025, 5:40 PM Nextensa NV/SA : Information on the total number of voting rights and shares In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the 'Company') announces the following information following the grant of double voting rights to certain of the shares in the Company. Situation on 18 December 2025 : Total capital : EUR 111,856,017.40Total number of securities carrying voting rights ...

DEME’s Dredging & Infra segment has secured two marine works contracts in Southern Europe, highlighting its expertise in environmental remediation and coastal protection. In Italy, DEME will deliver marine works for the prestigious 38th America’s Cup sailing competition in Naples, including offshore breakwaters and seabed remediation at the Bagnoli-Coroglio site. Meanwhile, in Spain, DEME will restore three beaches along the Valencian coastline through a large-scale nourishment project, to combat erosion an ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2025 Investor's Business Daily, LLC. All Rights Reserved. About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Check ...

(Bloomberg) -- UBS Group AG is set to begin its latest wave of job cuts in mid-January, according to people familiar with the matter. That step will be followed by another round later in 2026 as UBS intends to switch off computer systems it acquired when it took over its former competitor in 2023, the people said, asking not to be named discussing internal matters.UBS is entering the final year of its historic integration of Credit Suisse, which it bought in an emergency government-brokered deal in 2023. Th ...